For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$406.09
Thesis
Amgen is a diversified large-cap biopharma using its scale and commercial reach to push into the obesity market. Its monthly-dosed incretin candidate offers a differentiated profile against an established injectable franchise.
Catalysts
- MariTide late-stage obesity readouts
- Label expansion into cardiometabolic indications
- Biosimilar and base-business cash generation funding the pipeline
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Aug 4Financial resultsSEC
Amgen 8-K filed with items 2.02 and 9.01 on financial results.
- Aug 4RegulatoryFDA
FDA supplemental submission (SUPPL-210) for Neulasta (BLA125031) dated 2026-08-04.
- Jul 31OtherSEC
Amgen 8-K discloses material cybersecurity incident under Item 1.05.
- Jun 23RegulatoryFDA
FDA supplemental submission (SUPPL-225) for PROLIA (BLA125320) filed 2026-06-23.
- May 19LeadershipSEC
Amgen filed 8-K (item 5.02) on officer or director changes.